N. Kiavue

ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics

F. Bidard, J. Pierga, G. Bataillon, 2019, Oncogene.

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial

M. Ychou, M. Stern, F. Bidard, 2019, Cells.

Trabectedin in advanced desmoplastic round cell tumors: a retrospective single-center series

P. Terrier, O. Mir, J. Adam, 2017, Anti-cancer drugs.

Clinical utility of circulating tumor cells: an update

F. Bidard, J. Pierga, A. Vasseur, 2020, Molecular oncology.

Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical Trial.

M. Espié, F. Bidard, J. Pierga, 2020, JAMA oncology.

Microsatellite instability detection in breast cancer using drop-off droplet digital PCR

A. Vincent-Salomon, I. Bièche, M. Stern, 2022, Oncogene.

Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy

F. Bidard, J. Pierga, P. Cottu, 2020, Breast cancer research : BCR.

Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial

M. Campone, F. Bidard, J. Pierga, 2021, British Journal of Cancer.

Clinical utility of circulating tumor cells: an update

F. Bidard, J. Pierga, A. Vasseur, 2020 .

Overall Survival With Circulating Tumor Cell Count–Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial

F. Bidard, V. Diéras, F. Dalenc, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.